trial

Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder

NCTId NCT06086184
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 32 (estimated)
Sponsored by Vivantes Netzwerk für Gesundheit GmbH
Primary completion 2025-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
32 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-10-16
Primary completion
2025-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
ACT group therapy

Sponsors

Vivantes Netzwerk für Gesundheit GmbHLead Sponsor

Investigators

1
Andreas Bechdolf, Prof. Dr.Study Director

Sites

1 total
Kreuzberg, Germany

Facts & assertions

4 sourced
Enrollment
32
Phase
NA
Primary Completion Date
2025-02
Status
UNKNOWN
relationships
The graph out of here
drug
ACT group therapy
drug
lead_sponsor
Vivantes Netzwerk für Gesundheit GmbH
company
indication
Psychotic Disorders
indication
Acceptance and Commitment Therapy
indication
Psychotic Disorders
indication
investigator
Andreas Bechdolf, Prof. Dr.
person